Next Article in Journal
Kinase Inhibitors that Increase the Sensitivity of Methicillin Resistant Staphylococcus aureus to β-Lactam Antibiotics
Next Article in Special Issue
Candida albicans Shed Msb2 and Host Mucins Affect the Candidacidal Activity of Salivary Hst 5
Previous Article in Journal
Immune Response to Human Metapneumovirus Infection: What We Have Learned from the Mouse Model
Previous Article in Special Issue
Systems Level Dissection of Candida Recognition by Dectins: A Matter of Fungal Morphology and Site of Infection
Article Menu

Export Article

Open AccessReview
Pathogens 2015, 4(4), 697-707;

Studies of Immune Responses in Candida vaginitis

Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy
Author to whom correspondence should be addressed.
Academic Editor: Sarah Gaffen
Received: 24 June 2015 / Revised: 23 September 2015 / Accepted: 30 September 2015 / Published: 9 October 2015
(This article belongs to the Special Issue Candida Albicans Infections)
Full-Text   |   PDF [288 KB, uploaded 9 October 2015]   |  


The widespread occurrence of vaginal candidiasis and the development of resistance against anti-fungal agents has stimulated interest in understanding the pathogenesis of this disease. The aim of our work was to characterize, in an animal model of vaginal candidiasis, the mechanisms that play a role in the induction of mucosal immunity against C. albicans and the interaction between innate and adaptive immunity. Our studies evidenced the elicitation of cell-mediated immunity (CMIs) and antibody (Abs)-mediated immunity with a Th1 protective immunity. An immune response of this magnitude in the vagina was very encouraging to identify the proper targets for new strategies for vaccination or immunotherapy of vaginal candidiasis. Overall, our data provide clear evidence that it is possible to prevent C. albicans vaginal infection by active intravaginal immunization with aspartyl proteinase expressed as recombinant protein. This opens the way to a modality for anti-Candida protection at the mucosa. The recombinant protein Sap2 was assembled with virosomes, and a vaccine PEVION7 (PEV7) was obtained. The results have given evidence that the vaccine, constituted of virosomes and Secretory aspartyl proteinase 2 (Sap2) (PEV7), has an encouraging therapeutic potential for the treatment of recurrent vulvovaginal candidiasis. View Full-Text
Keywords: Candida vaginitis; immune response; aspartyl proteinase; mucosal anti-Candida vaccine Candida vaginitis; immune response; aspartyl proteinase; mucosal anti-Candida vaccine

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

De Bernardis, F.; Arancia, S.; Sandini, S.; Graziani, S.; Norelli, S. Studies of Immune Responses in Candida vaginitis. Pathogens 2015, 4, 697-707.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pathogens EISSN 2076-0817 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top